Impact of treatment on FACT-G score and domains
| DR prednisone/DMARD | Placebo/DMARD | Treatment difference (95% CI) | |||||
|---|---|---|---|---|---|---|---|
| Mean total/domain score (SD) | Baseline | Week 12 | Difference | Baseline | Week 12 | Difference | |
| FACT-G ( score) | 67.3 (16.6) | 71.1 (18.0) | 3.6 (10.4) | 68.1 (14.5) | 69.1 (15.3) | 1.0 (9.8) | 2.6 (0.4 to 4.8)* |
| Range | 14–105 | 27–107 | 29–96 | 32–104 | |||
| Physical well-being | 16.7 (5.3) | 18.8 (5.7) | 2.0 (4.1) | 16.8 (5.6) | 17.9 (5.0) | 1.1 (3.9) | 0.9 (0.1 to 1.8)* |
| Social/family well-being | 20.1 (5.6) | 19.9 (6.3) | −0.26 (5.0) | 20.6 (4.9) | 20.0 (5.1) | −0.6 (4.2) | 0.2 (−0.8, 1.2) |
| Emotional well-being | 14.5 (5.1) | 15.5 (5.3) | 1.0 (3.4) | 14.6 (4.7) | 15.5 (4.9) | 0.9 (2.9) | 0.1 (−0.6 to 0.8) |
| Functional well-being | 16.0 (5.8) | 17.0 (5.6) | 1.0 (4.1) | 16.2 (5.3) | 16.0 (5.4) | −0.21 (4.2) | 1.2 (0.3 to 2.0)** |
*p≤0.0297.
**p=0.0065.
DMARD, disease-modifying antirheumatic drug; DR, delayed-release; FACT-G, Functional Assessment of Cancer Therapy-General.